A number of therapeutic agents have been developed including small molecules that inhibit these key signaling pathways including agents that target BCR-mediated kinase signaling pathways and disrupt CLL cell-microenvironment interactions [3,4]. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.